Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Canadian (TSX) Pharma Industry Analysis

UpdatedJun 29, 2026
DataAggregated Company Financials
Companies54
  • 7D-0.09%
  • 3M26.3%
  • 1Y54.4%
  • YTD-0.7%

The Pharma is pretty flat in the last 7 days, but Apotex Health has stood out, gaining 7.0%. The past year has been better, since the industry has gained 54% in that time. Looking forward, earnings are forecast to grow by 14% annually.

Industry Valuation and Performance

Has the Canadian Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Tue, 30 Jun 2026CA$14.0bCA$10.7b-CA$1,735,065,856.358.8x-8.1x1.3x
Thu, 28 May 2026CA$16.1bCA$12.2b-CA$1,894,257,182.778.1x-8.5x1.3x
Sat, 25 Apr 2026CA$15.8bCA$11.2b-CA$1,666,746,960.2314.8x-9.5x1.4x
Mon, 23 Mar 2026CA$13.2bCA$11.3b-CA$1,701,194,077.0211.5x-7.7x1.2x
Wed, 18 Feb 2026CA$14.3bCA$11.2b-CA$1,898,020,108.9314.9x-7.5x1.3x
Fri, 16 Jan 2026CA$17.0bCA$11.3b-CA$1,959,031,887.0516.3x-8.7x1.5x
Sun, 14 Dec 2025CA$19.2bCA$11.2b-CA$1,911,998,737.3214.8x-10x1.7x
Tue, 11 Nov 2025CA$15.2bCA$11.3b-CA$1,876,410,918.5517.8x-8.1x1.4x
Thu, 09 Oct 2025CA$18.4bCA$11.2b-CA$2,036,511,751.4235.8x-9x1.6x
Sat, 06 Sep 2025CA$15.9bCA$11.2b-CA$2,031,100,344.4338.1x-7.8x1.4x
Mon, 04 Aug 2025CA$11.8bCA$11.8b-CA$2,580,662,352.2716.7x-4.6x1x
Wed, 02 Jul 2025CA$9.7bCA$11.7b-CA$2,515,850,664.9517x-3.8x0.8x
Fri, 30 May 2025CA$23.2bCA$11.8b-CA$2,396,620,795.0717.5x-9.7x2x
Sun, 27 Apr 2025CA$10.5bCA$11.9b-CA$2,537,137,906.5420.2x-4.1x0.9x
Tue, 25 Mar 2025CA$10.5bCA$12.3b-CA$2,567,787,653.6519.9x-4.1x0.9x
Thu, 20 Feb 2025CA$12.3bCA$12.1b-CA$2,212,835,656.1422.9x-5.5x1x
Sat, 18 Jan 2025CA$12.2bCA$12.2b-CA$2,421,943,229.6529.8x-5x1x
Mon, 16 Dec 2024CA$12.7bCA$12.0b-CA$2,588,051,717.1821.9x-4.9x1.1x
Wed, 13 Nov 2024CA$13.0bCA$11.9b-CA$2,631,380,295.5615.1x-4.9x1.1x
Fri, 11 Oct 2024CA$18.3bCA$11.7b-CA$2,697,603,068.9017.2x-6.8x1.6x
Sun, 08 Sep 2024CA$17.1bCA$11.6b-CA$2,699,993,509.6420x-6.4x1.5x
Tue, 06 Aug 2024CA$18.8bCA$11.7b-CA$3,096,658,580.3919.3x-6.1x1.6x
Thu, 04 Jul 2024CA$18.8bCA$11.7b-CA$3,225,203,624.5719.2x-5.8x1.6x
Sat, 01 Jun 2024CA$21.1bCA$11.9b-CA$3,474,747,660.6412.8x-6.1x1.8x
Mon, 29 Apr 2024CA$22.9bCA$11.8b-CA$3,444,223,192.038.4x-6.7x1.9x
Wed, 27 Mar 2024CA$23.2bCA$11.9b-CA$3,504,102,648.099.3x-6.6x2x
Fri, 23 Feb 2024CA$21.8bCA$12.0b-CA$4,642,695,320.799.4x-4.7x1.8x
Sun, 21 Jan 2024CA$20.4bCA$12.3b-CA$6,754,384,129.009.6x-3x1.6x
Tue, 19 Dec 2023CA$17.6bCA$12.3b-CA$6,738,434,260.008.2x-2.6x1.4x
Thu, 16 Nov 2023CA$17.5bCA$12.4b-CA$6,689,449,134.008.6x-2.6x1.4x
Sat, 14 Oct 2023CA$18.3bCA$12.4b-CA$7,333,238,247.0013.2x-2.5x1.5x
Mon, 11 Sep 2023CA$20.7bCA$13.0b-CA$7,922,680,059.0015.2x-2.6x1.6x
Wed, 09 Aug 2023CA$15.1bCA$13.3b-CA$9,749,939,151.0012x-1.5x1.1x
Fri, 07 Jul 2023CA$16.0bCA$13.3b-CA$9,544,539,622.0012x-1.7x1.2x
Price to Earnings Ratio

-1.7x


Total Market Cap: CA$16.0bTotal Earnings: -CA$9,544,539,622.00Total Revenue: CA$13.3bTotal Market Cap vs Earnings and Revenue0%0%0%
Canadian Pharma Industry Price to Earnings3Y Average -5.7x202420252026
Current Industry PE
  • Investors are relatively neutral on the Canadian Pharmaceuticals industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PS ratio of 1.4x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have improved over the last three years.
  • Meanwhile revenues for these companies have declined 6.7% per year.
  • This means that less sales are being generated overall, but since the cost of doing business is lower, losses have been shrinking.

Industry Trends

Which industries have driven the changes within the Canadian Healthcare industry?

CA Market-0.35%
Healthcare1.43%
Pharma-0.093%
Pharma-0.093%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
APTX Apotex HealthCA$32.327.0%
+CA$484.4m		n/aPE19.8x
CURA Curaleaf HoldingsCA$14.465.2%
+CA$190.2m		319.1%PS2.1x
CRON Cronos GroupCA$4.037.5%
+CA$104.6m		54.4%PS6.6x
VRNO Verano HoldingsCA$8.4610.7%
+CA$59.8m		148.8%PS0.5x
GUD Knight TherapeuticsCA$9.704.2%
+CA$38.3m		66.4%PE169.8x

Latest News

CRON
CA$4.03
Cronos Group
7D
7.5%
1Y
54.4%
Narrative Update • Jun 28

CRON: Partial Rescheduling And Buybacks Will Support A Stronger Outlook

Analysts have raised their Cronos Group price target by CA$0.50 to CA$5.50, citing revised assumptions around higher projected revenue growth, a different discount rate, and updated margin and P/E expectations following recent research commentary and a more favorable view on partial cannabis re scheduling. Analyst Commentary Recent research on Cronos Group highlights how shifting views on cannabis policy and updated valuation work are feeding into more constructive analyst sentiment on the stock.
CURA
CA$14.46
Curaleaf Holdings
7D
5.2%
1Y
319.1%
BNXT
CA$0.32
BioNxt Solutions
7D
-13.5%
1Y
-42.9%
MDP
CA$4.49
Medexus Pharmaceuticals
7D
10.3%
1Y
41.6%
VRNO
CA$8.17
Verano Holdings
7D
7.9%
1Y
140.3%
GUD
CA$9.70
Knight Therapeutics
7D
4.2%
1Y
66.4%
Narrative Update • Jun 25

GUD: Latin American Drug Launches And Renewed Coverage Will Drive Future Repricing

Analysts have lifted their price target on Knight Therapeutics by CA$1, reflecting updated assumptions for slightly higher revenue growth and profit margins, along with a modestly lower future P/E multiple. Analyst Commentary Recent research coverage on Knight Therapeutics points to a more constructive tone, with bullish analysts emphasizing the refreshed price target and renewed attention on the stock.
GTII
CA$10.66
Green Thumb Industries
7D
0.6%
1Y
43.1%
Narrative Update • Jun 25

GTII: Partial Cannabis Rescheduling Will Support Future Rerating Despite Medical Efficacy Concerns

Analysts have lifted their Green Thumb Industries price target by CA$0.55, citing updated assumptions around revenue growth, profit margins, future P/E expectations and supportive sector commentary following recent research on cannabis rescheduling. Analyst Commentary Recent research on Green Thumb Industries points to a more constructive tone from bullish analysts, who are revisiting their models in light of updated company assumptions and evolving views on cannabis rescheduling.
HLS
CA$4.26
HLS Therapeutics
7D
-4.7%
1Y
-11.3%
Narrative Update • Jun 23

HLS: Future Upside Will Depend On Executing Reaffirmed 2026 Earnings Guidance

Analysts have adjusted their CA$5 price target on HLS Therapeutics in light of updated assumptions for revenue growth, profit margins, and future P/E. This reflects a refined view of the stock's potential value.
CPH
CA$16.18
Cipher Pharmaceuticals
7D
-0.9%
1Y
29.0%
Narrative Update • Jun 23

CPH: Share Repurchases And Higher Margins Will Support Future Upside

Analysts have nudged their fair value estimate for Cipher Pharmaceuticals higher, lifting the implied price target from CA$21.00 to about CA$22.25. This reflects updated assumptions around revenue growth, profit margins and future P/E expectations.
XLY
CA$0.17
Auxly Cannabis Group
7D
-10.3%
1Y
75.0%
APTX
CA$32.32
Apotex Health
7D
7.0%
1Y
n/a
Analysis Article • Jun 20

Apotex Health (TSX:APTX) Stock Could Be 51.7% Below Fair Value After Its IPO

IPO, early trading moves and why Apotex Health is suddenly in focus Apotex Health (TSX:APTX) has quickly drawn investor attention after completing a roughly CA$1.5b IPO at CA$24 per share, with early trading marked by share price swings and debate over what the new listing is worth. The offering combined a treasury sale of new shares with a secondary sale by existing holders. This structure put fresh capital on the company’s balance sheet while giving SK Capital Partners and other...
VREO
CA$12.58
Vireo Growth
7D
-15.2%
1Y
-27.7%
GRIN
CA$0.51
Grown Rogue International
7D
-17.7%
1Y
-5.6%
NVRS
CA$1.00
Noveris Health Sciences
7D
-33.3%
1Y
300.0%
CWEB
CA$0.44
Charlotte's Web Holdings
7D
27.5%
1Y
252.0%
PREV
CA$0.015
PreveCeutical Medical
7D
-25.0%
1Y
-50.0%